+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alpha-1 Antitrypsin Deficiency Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • PDF Icon

    Report

  • 173 Pages
  • October 2023
  • Region: Global
  • TechSci Research
  • ID: 5893509
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Alpha-1 Antitrypsin Deficiency Disease Market reached a valuation of USD 1809.36 Million in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.49% up to 2028 and expected to reach USD 2627.18 Million by 2028. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is an uncommon genetic disorder impacting the lungs and liver. It arises due to insufficient levels of the alpha-1 antitrypsin protein, resulting in an elevated vulnerability to lung and liver diseases. Despite its rarity, Alpha-1 Antitrypsin Deficiency Disease significantly affects patients' quality of life and healthcare systems. As research advances and awareness spreads, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing changes, presenting both challenges and opportunities.

Alpha-1 antitrypsin is a liver-produced protein pivotal in safeguarding lungs against inflammation-induced damage from enzymes. In cases of Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to misfolded protein accumulation in the liver instead of release into the bloodstream. This deficiency heightens susceptibility to lung ailments like chronic obstructive pulmonary disease (COPD) and liver conditions such as cirrhosis.

While the Alpha-1 Antitrypsin Deficiency Disease market is relatively compact due to the disease's rarity, it garners attention from researchers, pharmaceutical firms, and healthcare providers. Notable players in diagnostics, treatments, and therapies concentrate on addressing the underlying deficiency and managing linked complications. Biotechnology, genomics, and personalized medicine progress yield targeted, effective treatments for Alpha-1 Antitrypsin Deficiency Disease, potentially revolutionizing patient outcomes.

Government initiatives and research funding propel the global Alpha-1 Antitrypsin Deficiency Disease market. As rare disease awareness, like Alpha-1 Antitrypsin Deficiency Disease, heightens, policies and programs supporting research, diagnosis, and treatment development gain traction. Funds for research projects, clinical trials, and patient support captivate pharmaceutical companies and researchers, spurring accelerated advancements.

Primary Market Drivers

1. Increasing Patient Base: The Global Alpha-1 Antitrypsin Deficiency Disease Market witnesses substantial growth due to a rising patient population. Though a rare genetic disorder, underreported cases and misdiagnoses result in a larger target group as awareness and diagnostic precision improve. Heightened cases prompt increased pharmaceutical and research focus, driving market expansion.

2. Regulatory Backing: Collaborative efforts among researchers, clinicians, patients, advocacy groups, and pharmaceutical firms catalyze advancements in Alpha-1 Antitrypsin Deficiency Disease understanding, treatment, and patient care. Cross-institutional consortia, pharmaceutical-academic collaborations, and digital data sharing transform traditional research and treatment approaches, fostering progress.

Key Market Challenges

1. Underdiagnosis and Misdiagnosis: A substantial challenge in the Alpha-1 Antitrypsin Deficiency Disease market lies in its underdiagnosis and misdiagnosis. Many patients remain undiagnosed or misdiagnosed as other lung conditions, delaying accurate treatment strategies.

2. Limited Awareness: The rarity of Alpha-1 Antitrypsin Deficiency Disease results in limited awareness among the public and healthcare professionals, causing delayed diagnosis and insufficient support.

3. Complex Treatment: Developing effective treatments for Alpha-1 Antitrypsin Deficiency Disease is intricate due to its genetic nature and dual lung-liver complications, necessitating therapies addressing both aspects.

Key Market Trends

1. Technological Advancements: Technological breakthroughs in genetic screening enable early Alpha-1 Antitrypsin Deficiency Disease detection, allowing proactive intervention. Precision medicine tailors treatment based on genetic makeup, enhancing efficacy. Gene therapies and editing explore treating the genetic root, potentially transforming disease management.

2. Collaborative Efforts: Cross-disciplinary collaborations accelerate Alpha-1 Antitrypsin Deficiency Disease understanding and management. Research consortia, pharmaceutical-academic partnerships, and patient advocacy groups expedite research, innovation, and treatment development.

Segment Insights

1. Product: In 2022, the Alpha-1 Proteinase Inhibitor segment led the Alpha-1 Antitrypsin Deficiency Disease market and is expected to continue its growth trajectory. Replenishing deficient A1PI levels through enzyme replacement therapy (ERT) helps alleviate symptoms, slowing lung damage progression.

2. Distribution Channel: In 2022, Hospital pharmacies dominated the market, driven by the comprehensive care Alpha-1 Antitrypsin Deficiency Disease patients require, involving specialists from various disciplines.

Regional Insights

North America: This research hub boasts leading institutions, research centers, and pharmaceutical companies, propelling Alpha-1 Antitrypsin Deficiency Disease understanding, diagnostics, and treatments. Clinical trials predominantly occur here, giving early access to new therapies and consolidating North America's market leadership. The region's disposable income, healthcare spending, and coverage bolster market dominance.

Key Market Players

  • Shire plc
  • GlaxoSmithKline plc
  • CSL Behring
  • AstraZeneca Plc.
  • Grifols S.A.
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim International GmbH
  • Kamada Pharmaceuticals
  • Pfizer Inc.
  • Baxter International Inc.

Report Scope:

In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

  • Alpha-1 Proteinase Inhibitor
  • Bronchodilato
  • Corticosteroid
  • Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

  • Injection
  • Oral
  • Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

  • Hospitals Pharmacy
  • Retail Pharmacies
  • Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (Shares of Top 5 Market Players)
5.3. Market Map
5.3.1. By Product
5.3.2. By Route of Administration
5.3.3. By Distribution Channel
5.3.4. By Region
6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
6.2.4.1.1. Market Size & Forecast
6.2.4.1.1.1. By Value
6.2.4.1.2. Market Share & Forecast
6.2.4.1.2.1. By Product
6.2.4.1.2.2. By Route of Administration
6.2.4.1.2.3. By Distribution Channel (
6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
6.2.4.2.1. Market Size & Forecast
6.2.4.2.1.1. By Value
6.2.4.2.2. Market Share & Forecast
6.2.4.2.2.1. By Product
6.2.4.2.2.2. By Route of Administration
6.2.4.2.2.3. By Distribution Channel
6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
6.2.4.3.1. Market Size & Forecast
6.2.4.3.1.1. By Value
6.2.4.3.2. Market Share & Forecast
6.2.4.3.2.1. By Test
6.2.4.3.2.2. By Route of Administration
6.2.4.3.2.3. By Distribution Channel
7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
7.2.4.1.1. Market Size & Forecast
7.2.4.1.1.1. By Value
7.2.4.1.2. Market Share & Forecast
7.2.4.1.2.1. By Product
7.2.4.1.2.2. By Route of Administration
7.2.4.1.2.3. By Distribution Channel
7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
7.2.4.2.1. Market Size & Forecast
7.2.4.2.1.1. By Value
7.2.4.2.2. Market Share & Forecast
7.2.4.2.2.1. By Product
7.2.4.2.2.2. By Route of Administration
7.2.4.2.2.3. By Distribution Channel
7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
7.2.4.3.1. Market Size & Forecast
7.2.4.3.1.1. By Value
7.2.4.3.2. Market Share & Forecast
7.2.4.3.2.1. By Product
7.2.4.3.2.2. By Route of Administration
7.2.4.3.2.3. By Distribution Channel
7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
7.2.4.4.1. Market Size & Forecast
7.2.4.4.1.1. By Value
7.2.4.4.2. Market Share & Forecast
7.2.4.4.2.1. By Product
7.2.4.4.2.2. By Route of Administration
7.2.4.4.2.3. By Distribution Channel
7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
7.2.4.5.1. Market Size & Forecast
7.2.4.5.1.1. By Value
7.2.4.5.2. Market Share & Forecast
7.2.4.5.2.1. By Product
7.2.4.5.2.2. By Route of Administration
7.2.4.5.2.3. By Distribution Channel
8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
8.2.4.1.1. Market Size & Forecast
8.2.4.1.1.1. By Value
8.2.4.1.2. Market Share & Forecast
8.2.4.1.2.1. By Product
8.2.4.1.2.2. By Route of Administration
8.2.4.1.2.3. By Distribution Channel
8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
8.2.4.2.1. Market Size & Forecast
8.2.4.2.1.1. By Value
8.2.4.2.2. Market Share & Forecast
8.2.4.2.2.1. By Product
8.2.4.2.2.2. By Route of Administration
8.2.4.2.2.3. By Distribution Channel
8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
8.2.4.3.1. Market Size & Forecast
8.2.4.3.1.1. By Value
8.2.4.3.2. Market Share & Forecast
8.2.4.3.2.1. By Product
8.2.4.3.2.2. By Route of Administration
8.2.4.3.2.3. By Distribution Channel
8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
8.2.4.4.1. Market Size & Forecast
8.2.4.4.1.1. By Value
8.2.4.4.2. Market Share & Forecast
8.2.4.4.2.1. By Product
8.2.4.4.2.2. By Route of Administration
8.2.4.4.2.3. By Distribution Channel
8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
8.2.4.5.1. Market Size & Forecast
8.2.4.5.1.1. By Value
8.2.4.5.2. Market Share & Forecast
8.2.4.5.2.1. By Product
8.2.4.5.2.2. By Route of Administration
8.2.4.5.2.3. By Distribution Channel
9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
9.2.4.1.1. Market Size & Forecast
9.2.4.1.1.1. By Value
9.2.4.1.2. Market Share & Forecast
9.2.4.1.2.1. By Product
9.2.4.1.2.2. By Route of Administration
9.2.4.1.2.3. By Distribution Channel
9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
9.2.4.2.1. Market Size & Forecast
9.2.4.2.1.1. By Value
9.2.4.2.2. Market Share & Forecast
9.2.4.2.2.1. By Product
9.2.4.2.2.2. By Route of Administration
9.2.4.2.2.3. By Distribution Channel
9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
9.2.4.3.1. Market Size & Forecast
9.2.4.3.1.1. By Value
9.2.4.3.2. Market Share & Forecast
9.2.4.3.2.1. By Product
9.2.4.3.2.2. By Route of Administration
9.2.4.3.2.3. By Distribution Channel
10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
10.2.4.1.1. Market Size & Forecast
10.2.4.1.1.1. By Value
10.2.4.1.2. Market Share & Forecast
10.2.4.1.2.1. By Product
10.2.4.1.2.2. By Route of Administration
10.2.4.1.2.3. By Distribution Channel
10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
10.2.4.2.1. Market Size & Forecast
10.2.4.2.1.1. By Value
10.2.4.2.2. Market Share & Forecast
10.2.4.2.2.1. By Product
10.2.4.2.2.2. By Route of Administration
10.2.4.2.2.3. By Distribution Channel
10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
10.2.4.3.1. Market Size & Forecast
10.2.4.3.1.1. By Value
10.2.4.3.2. Market Share & Forecast
10.2.4.3.2.1. By Product
10.2.4.3.2.2. By Route of Administration
10.2.4.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Competitive Landscape
13.1. Shire plc
13.2. GlaxoSmithKline plc
13.3. CSL Behring
13.4. AstraZeneca Plc.
13.5. Grifols S.A.
13.6. Teva Pharmaceutical Industries
13.7. Boehringer Ingelheim International GmbH
13.8. Kamada Pharmaceuticals
13.9. Pfizer Inc.
13.10. Baxter International Inc.
14. Strategic Recommendations15. About the Publisher & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Shire plc
  • GlaxoSmithKline plc
  • CSL Behring
  • AstraZeneca Plc.
  • Grifols S.A.
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim International GmbH
  • Kamada Pharmaceuticals
  • Pfizer Inc.
  • Baxter International Inc.

Table Information

Report AttributeDetails
No. of Pages173
PublishedOctober 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 1809.36 Million
Forecasted Market Value ( USD ) by 2028 $ 2627.18 Million
Compound Annual Growth Rate6.4%
Regions CoveredGlobal

Related Topics

Related Reports

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2024 - Product Image

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Insight, 2024

  • Clinical Trials
  • 70 Pages
  • Global
From
Alport Syndrome - Pipeline Insight, 2024 - Product Image

Alport Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Global Erythropoietin Stimulating Agents Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Global Erythropoietin Stimulating Agents Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 172 Pages
  • Global
From
Hepatitis Drugs Global Market Report 2024 - Product Image

Hepatitis Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Liver Fibrosis Market Report and Forecast 2024-2032 - Product Image

Liver Fibrosis Market Report and Forecast 2024-2032

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.